BusinessArch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic ResistanceBy Nasdaq OMXMar 27, 2018, 1:08 PM UTC
